Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.

Journal of cachexia, sarcopenia and muscle·2025

Same author

A Man in His 50s With Dyspnea and Eosinophilia.

JAMA cardiology·2024

Same author

Association of an impaired GH-IGF-I axis with cardiac wasting in patients with advanced cancer.

Clinical research in cardiology : official journal of the German Cardiac Society·2024

Same author

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19.

International journal of molecular sciences·2023

Same author

Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.

The European respiratory journal·2023

Same author

Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation.

Biomedicines·2023

Search research articles

Related Experiment Video

Updated: May 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Gender differences in anticoagulation and antithrombotic therapy.

¹Charité-Universitätsmedizin Berlin, Berlin, Germany. ursula.rauch@charite.de

Handbook of Experimental Pharmacology

|October 3, 2012

Summary

Gender disparities exist in cardiovascular disease treatment, with women experiencing increased thromboembolic events. Understanding these differences is crucial for tailoring antithrombotic therapies and improving patient outcomes.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Cardiology
Pharmacology
Gender Studies

Background:

Cardiovascular disease (CVD) is a leading global cause of death and illness.
Thromboembolic event rates are rising in women, unlike in men.
Current antithrombotic therapies are based on clinical trials with limited representation of diverse populations, including women.

Purpose of the Study:

To provide an overview of existing data on gender differences in anticoagulation and antithrombotic therapy.
To highlight the impact of gender on clinical presentation, outcomes, and treatment effectiveness in cardiovascular diseases.
To address the generalization challenges of clinical trial results to underrepresented subgroups.

Main Methods:

Review of current clinical studies and available data on gender-related differences in antithrombotic therapy.
Analysis of factors contributing to gender disparities in platelet biology and coagulation.
Examination of effectiveness and adverse event rates of antithrombotic treatments across genders.

Main Results:

Significant gender-related differences observed in the clinical presentation and outcomes of cardiovascular diseases.
Variations in platelet biology and coagulation reactions contribute to differing rates of thromboembolic and bleeding events between genders.
The effectiveness and safety profiles of antithrombotic therapies may differ between men and women.

Conclusions:

Gender is a significant factor influencing cardiovascular disease, thromboembolic events, and response to antithrombotic therapies.
Further research and tailored treatment strategies are needed to address gender-specific needs in anticoagulation and antithrombotic therapy.
Optimizing clinical benefit requires considering gender-related differences in treatment effectiveness and adverse events.